Bionorica SE
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1933-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.bionorica.de
Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea
Phase 3
Active, not recruiting
- Conditions
- Primary Dysmenorrhea
- Interventions
- Drug: PlaceboDrug: Vitex agnus-castus BNO 1095 (20 mg)
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 286
- Registration Number
- NCT06211049
- Locations
- 🇵🇱
Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. z o.o., Malbork, Poland
🇸🇪Karolinska University Hospital, WHO-centre, Stockholm, Sweden
🇩🇪Klinische Forschung Hamburg GmbH, Hamburg, Germany
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis
Not Applicable
Completed
- Conditions
- Atopic DiathesisEczema-prone Skin
- Interventions
- Other: Benchmark productOther: Atopi intensive care BNO 3731
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 44
- Registration Number
- NCT05807113
- Locations
- 🇩🇪
SGS proderm GmbH, Schenefeld, Germany
Skin Efficacy and Tolerability of a Cosmetic Product Combination Over 3 Months in Subjects With Atopic Eczema
Not Applicable
Active, not recruiting
- Conditions
- Atopic DermatitisEczema-Prone Skin
- Interventions
- Other: Body Lotion and Intensive Care
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 100
- Registration Number
- NCT05790083
- Locations
- 🇩🇪
SGS proderm GmbH, Schenefeld, Germany
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 4 Weeks of Use on Subjects With Atopic Dermatitis
Not Applicable
Completed
- Conditions
- Atopic DiathesisEczema-Prone Skin
- Interventions
- Other: Lotion BNO 3732Other: Body Lotion Benchmark product
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 44
- Registration Number
- NCT05786976
- Locations
- 🇩🇪
SGS proderm GmbH, Schenefeld, Germany
BX-1 in Spasticity Due to Multiple Sclerosis
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 397
- Registration Number
- NCT03756974
- Locations
- 🇪🇸
Investigative Site, Valencia, Spain
🇨🇿Investigative site, Hradec Králové, Czechia
Sinupret Extract Coated Tablets in Chronic Rhinosinusitis
Phase 3
Completed
- Conditions
- Chronic Rhinosinusitis
- Interventions
- Drug: Sinupret extract coated tabletsDrug: Placebo coated tablets
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 572
- Registration Number
- NCT02746042
- Locations
- 🇵🇱
Bionorica Investigative Site, Wroclaw, Poland
🇵🇱Bionorica Investigative Site 222, Zgierz, Poland
🇵🇱Bionorica Investigative Site 224, Zgierz, Poland
Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs
Phase 3
Completed
- Conditions
- Urinary Tract Infection
- Interventions
- Drug: Canephron® NDrug: Canephron® N-placebo
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 659
- Registration Number
- NCT02639520
- Locations
- 🇩🇪
Justus-Liebig-Universität, Giessen, Hessen, Germany
Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)
Phase 2
Completed
- Conditions
- Current Smokers
- Interventions
- Drug: administration of BronchipretDrug: administration of SinupretDrug: administration of Bronchipret PlaceboDrug: administration of Sinupret Placebo
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 56
- Registration Number
- NCT01928901
- Locations
- 🇧🇪
University Hospital Ghent, Ghent, Belgium
Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS
Phase 3
Terminated
- Conditions
- MastodyniaPremenstrual Syndrome
- Interventions
- Drug: 20mg VAC BNO 1095 FCTDrug: Placebo
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 96
- Registration Number
- NCT01870687
- Locations
- 🇩🇪
Private Doctor's office - Dr. Hannes Herold, Munich, Bavaria, Germany
Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Bionorica SE
- Target Recruit Count
- 927
- Registration Number
- NCT01706484
- Locations
- 🇧🇪
Claus Bachert, Prof. Dr., Ghent, Belgium
© Copyright 2025. All Rights Reserved by MedPath